Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review.
作者信息
Said Jordan Taylor, Elman Scott Andrew, Perez-Chada Lourdes Maria, Mita Carol, Merola Joseph F, LeBoeuf Nicole R
机构信息
Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
出版信息
J Am Acad Dermatol. 2022 Aug;87(2):399-400. doi: 10.1016/j.jaad.2022.02.030. Epub 2022 Feb 23.
Abstract
摘要
相似文献
1
Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review.免疫检查点抑制剂介导的银屑病的治疗：一项系统评价。
J Am Acad Dermatol. 2022 Aug;87(2):399-400. doi: 10.1016/j.jaad.2022.02.030. Epub 2022 Feb 23.
2
Why are immune adverse events so common with checkpoint inhibitor therapy?为什么免疫相关不良事件在检查点抑制剂治疗中如此常见？
Ann Allergy Asthma Immunol. 2021 Jun;126(6):608-610. doi: 10.1016/j.anai.2021.03.016. Epub 2021 Mar 25.
3
Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye.免疫检查点抑制剂相关神经毒性：远不止所见那么简单。
Immunol Lett. 2020 May;221:72-74. doi: 10.1016/j.imlet.2020.02.007. Epub 2020 Feb 21.
4
[Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].[免疫检查点抑制剂诱导的重症肌无力：从诊断到治疗]
Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):685-688. doi: 10.3779/j.issn.1009-3419.2020.102.25. Epub 2020 Aug 5.
5
Visceral Aneurysm Formation and Intraabdominal Hemorrhage Associated with Immune Checkpoint Inhibitor Therapy.与免疫检查点抑制剂治疗相关的内脏动脉瘤形成和腹腔内出血
J Vasc Interv Radiol. 2021 Jan;32(1):151-152. doi: 10.1016/j.jvir.2020.08.003. Epub 2020 Dec 2.
6
Onset of psoriasis with immune checkpoint inhibitor therapy: A systematic review.免疫检查点抑制剂治疗引发银屑病：一项系统综述。
J Am Acad Dermatol. 2024 Feb;90(2):392-395. doi: 10.1016/j.jaad.2023.09.070. Epub 2023 Oct 4.
7
Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast.用阿普斯特成功治疗免疫检查点抑制剂诱导的银屑病。
Eur J Cancer. 2019 Mar;110:107-109. doi: 10.1016/j.ejca.2019.01.010. Epub 2019 Feb 18.
8
Immune checkpoint inhibitor-induced radiation recall myositis.免疫检查点抑制剂诱导的放射性回忆性肌炎。
Rheumatology (Oxford). 2023 Jun 1;62(6):e191-e192. doi: 10.1093/rheumatology/keac636.
9
Loss of epidermal Langerhans cells in psoriasiform lesions of de novo induced or worsened pre-existing psoriasis following uses of immune checkpoint inhibitors.免疫检查点抑制剂使用后新诱导或加重的银屑病样皮损中表皮朗格汉斯细胞缺失。
J Dermatol. 2022 Sep;49(9):916-920. doi: 10.1111/1346-8138.16427. Epub 2022 May 12.
10
Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.晚期黑色素瘤患者在免疫检查点抑制治疗过程中出现的白癜风样皮损
Eur J Dermatol. 2020 Feb 1;30(1):72-73. doi: 10.1684/ejd.2020.3732.
引用本文的文献
1
Toripalimab induces exacerbation of psoriasis in an esophageal cancer patient: a case report.托法替布致一名食管癌患者银屑病病情加重：病例报告
Front Oncol. 2025 Aug 27;15:1596818. doi: 10.3389/fonc.2025.1596818. eCollection 2025.
2
Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies.癌症治疗的皮肤反应及其他未得到充分重视的皮肤科副作用
Curr Treat Options Oncol. 2025 Aug 14. doi: 10.1007/s11864-025-01333-5.
3
Clinical features, treatment, and outcomes of nivolumab induced psoriasis.纳武单抗诱发银屑病的临床特征、治疗及转归
Invest New Drugs. 2025 Feb;43(1):42-49. doi: 10.1007/s10637-024-01494-4. Epub 2024 Dec 26.
4
Association of vitiligo with immune-checkpoint inhibitor therapy: A systematic review.白癜风与免疫检查点抑制剂治疗的关联：一项系统综述。
JAAD Int. 2024 Nov 14;18:119-121. doi: 10.1016/j.jdin.2024.10.005. eCollection 2025 Feb.
5
Research Progress on Chitosan Microneedle Arrays in Transdermal Drug Delivery.壳聚糖微针阵列在经皮给药中的研究进展
Int J Nanomedicine. 2024 Dec 3;19:12957-12973. doi: 10.2147/IJN.S487313. eCollection 2024.
6
Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents.靶向癌症治疗时代的银屑病：关于接受新型抗肿瘤药物治疗的肿瘤患者新发和既往存在银屑病的系统评价
Dermatol Ther (Heidelb). 2024 Jul;14(7):1755-1766. doi: 10.1007/s13555-024-01198-w. Epub 2024 Jun 22.
7
Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors.PD-1 检查点抑制剂引起的银屑病新发或恶化。
An Bras Dermatol. 2024 May-Jun;99(3):425-432. doi: 10.1016/j.abd.2023.09.003. Epub 2024 Feb 21.
8
Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events.用于治疗免疫相关皮肤不良事件的免疫调节全身疗法的安全性。
Pharmaceuticals (Basel). 2023 Nov 15;16(11):1610. doi: 10.3390/ph16111610.
9
Updates in toxicities associated with immune checkpoint inhibitors.免疫检查点抑制剂相关毒性的最新进展。
Expert Rev Clin Immunol. 2023 Jul-Dec;19(9):1117-1129. doi: 10.1080/1744666X.2023.2221434. Epub 2023 Jun 5.
10
Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors.免疫检查点抑制剂相关反向银屑病亚型的患病率。
Immunother Adv. 2022 Sep 23;2(1):ltac016. doi: 10.1093/immadv/ltac016. eCollection 2022.
本文引用的文献
1
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.免疫检查点介导的银屑病：来自欧洲皮肤不良反应与肿瘤药物网络（ENCADO）组的 115 例患者的多中心欧洲研究。
J Am Acad Dermatol. 2021 May;84(5):1310-1320. doi: 10.1016/j.jaad.2020.08.137. Epub 2020 Dec 3.
2
Low gene expression of TNF, IL17A, IL23A, and IL12B in tumors: A safety surrogate to predict cancer survival associated with biologic therapies.肿瘤中TNF、IL17A、IL23A和IL12B的低基因表达：预测与生物疗法相关的癌症生存的安全性替代指标。
J Am Acad Dermatol. 2021 Jul;85(1):249-252. doi: 10.1016/j.jaad.2020.08.050. Epub 2020 Aug 18.
3
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.NCCN 指南解读：免疫治疗相关毒性的管理，版本 1.2020。
J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012.
4
Treatment Outcomes of Immune-Related Cutaneous Adverse Events.免疫相关性皮肤不良反应的治疗结果。
J Clin Oncol. 2019 Oct 20;37(30):2746-2758. doi: 10.1200/JCO.18.02141. Epub 2019 Jun 19.
Zotero 插件